List of Excipients in Branded Drug OSELTAMIVIR PHOSPHATE FOR ORAL SUSPENSION

« Back to Dashboard

Generic Drugs Containing OSELTAMIVIR PHOSPHATE FOR ORAL SUSPENSION

Company	Ingredient	NDC	Excipient
EPIC PHARMA LLC	oseltamivir phosphate	42806-363	MONOSODIUM CITRATE
EPIC PHARMA LLC	oseltamivir phosphate	42806-363	SACCHARIN SODIUM
EPIC PHARMA LLC	oseltamivir phosphate	42806-363	SODIUM BENZOATE

What are the Most Frequently-Used Excipients in OSELTAMIVIR PHOSPHATE FOR ORAL SUSPENSION?

# Of NDCs	Excipient
5	MONOSODIUM CITRATE
5	SACCHARIN SODIUM
3	SILICON DIOXIDE

Oseltamivir Phosphate for Oral Suspension: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 9, 2026

Oseltamivir phosphate for oral suspension is a mature, genericized antiviral dosage form with commercial value concentrated in pediatric treatment, patients unable to swallow capsules, institutional stockpiles, and seasonal influenza demand. The principal formulation challenge is taste masking. The commercial opportunity is not a new active-ingredient patent position but a more stable, palatable, lower-waste, easier-to-reconstitute, and supply-secure liquid product.

What is oseltamivir phosphate for oral suspension?

Oseltamivir phosphate is the prodrug of oseltamivir, an influenza neuraminidase inhibitor. The oral suspension is used for treatment and prevention of influenza A and B and is particularly relevant for pediatric patients and adults who cannot use capsules.

The reference product is Tamiflu for oral suspension, supplied as a powder that is reconstituted with water to produce a 6 mg/mL suspension. The formulation is typically provided in a bottle with a calibrated oral dosing device. FDA labeling identifies the product as a powder for suspension rather than a ready-to-use liquid, which reduces shipping weight and improves long-term stability before reconstitution. [1]

Attribute	Commercial profile
Active ingredient	Oseltamivir phosphate
Active metabolite	Oseltamivir carboxylate
Dosage form	Powder for oral suspension
Standard concentration	6 mg/mL after reconstitution
Primary indication	Treatment and prophylaxis of influenza A and B
Main users	Pediatric patients, patients unable to swallow capsules, institutional users
Regulatory pathway for generics	ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act
Main formulation risk	Bitter taste and dose-measurement error
Main commercial cycle	Seasonal influenza demand, outbreak response, and government stockpiling

What excipients are used in oseltamivir oral suspension?

The reference formulation uses excipients for sweetening, buffering, preservation, flavoring, appearance, and powder handling. FDA labeling identifies sorbitol, monosodium citrate, sodium benzoate, saccharin sodium, titanium dioxide, and tutti-frutti flavor among the inactive ingredients. [1]

Excipient or excipient class	Primary function	Commercial and technical considerations
Sorbitol	Sweetener, bulking agent, mouthfeel modifier	Can improve palatability but may cause gastrointestinal effects at high exposure
Saccharin sodium	High-intensity sweetener	Supports bitterness reduction at low concentration
Tutti-frutti flavor	Flavor masking	Consumer acceptance depends on flavor intensity, persistence, and compatibility with the active
Sodium benzoate	Preservative	Supports microbiological control after reconstitution
Monosodium citrate	Buffering agent	Helps control pH and may support chemical stability
Titanium dioxide	Opacifier and color modifier	May face regulatory or customer restrictions in some markets
Suspending agents, if used in a follow-on formulation	Physical suspension control	Can reduce sedimentation and improve dose uniformity
Wetting agents, if used	Powder dispersion	May reduce clumping and improve reconstitution
Antifoam agents, if used	Foam control	Can improve filling, shaking, and dose withdrawal

The label composition of a generic product may differ from the reference product. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence, but it does not need to duplicate every inactive ingredient if the proposed excipients are suitable for the route, dosage form, patient population, and intended concentration. Excipients that alter absorption, microbial control, stability, or dose delivery require careful development and regulatory justification.

How should excipients be selected for oseltamivir suspension?

The excipient strategy should be built around five product attributes: taste, reconstitution, physical stability, microbiological protection, and dose accuracy.

Taste-masking strategy

Oseltamivir suspensions must manage active-ingredient bitterness. Sweeteners alone may not provide sufficient masking. A practical approach combines:

1. A bulk sweetener such as sorbitol.
2. A high-intensity sweetener such as saccharin sodium or sucralose.
3. A fruit flavor selected through pediatric sensory testing.
4. pH adjustment to reduce bitterness perception where compatible with chemical stability.
5. Particle-size and surface-area control to limit rapid release of dissolved or suspended drug in the mouth.

The flavor system should be tested after reconstitution and after storage under labeled in-use conditions. Flavor performance can change as volatile components dissipate or interact with packaging.

A product designed for broad pediatric use should avoid an overly strong flavor that creates refusal in younger children. The formulation should target acceptable taste across the labeled dosing range, including the higher doses used for adolescents and adults.

Suspension and reconstitution strategy

The reference product is a reconstituted suspension. Commercially important performance measures include:

• Time required to form a uniform suspension.
• Number of shakes required before dosing.
• Sedimentation rate.
• Redispersibility after standing.
• Resistance to caking.
• Dose uniformity during the bottle-use period.
• Compatibility with oral syringes and dosing adapters.

A formulation that settles rapidly can produce underdosing early in the bottle and overdosing later unless the label instructions are followed precisely. A formulation that forms a hard cake creates a greater risk because ordinary shaking may not restore uniformity.

Suspending polymers such as xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose blends, or other pharmaceutically accepted agents may improve physical stability. These excipients can also increase viscosity, slow dosing, trap air, or create a poor mouthfeel. The target is a low-viscosity suspension that remains uniform after routine shaking.

Preservation strategy

A multi-dose oral suspension requires microbiological control after reconstitution. Sodium benzoate is used in the reference formulation. A follow-on product should evaluate:

• Preservative effectiveness after reconstitution.
• pH dependence of preservative activity.
• Compatibility with the bottle and closure.
• Microbial ingress during repeated dosing.
• In-use stability under refrigerated and room-temperature conditions.
• Interaction with oral syringes and dosing adapters.

Preservative performance must be assessed in the final formulation, not inferred from the activity of the preservative alone. The suspension matrix, flavor components, sweeteners, pH, and packaging can change microbial protection.

Buffer and pH strategy

Monosodium citrate supports pH control. The formulation pH affects chemical stability, preservative performance, taste, and excipient compatibility. A narrow pH target should be established through forced-degradation and long-term stability studies.

A higher or lower pH may improve taste in some systems but can reduce preservative efficacy or accelerate degradation. The development program should therefore evaluate pH as an integrated formulation variable rather than a taste-only variable.

Sugar-free and allergen-conscious positioning

Sorbitol-based systems can support a sugar-free commercial position. This is relevant for parents, institutions, and patients managing sugar intake. The label must address the quantity of sorbitol and potential gastrointestinal effects when clinically relevant.

Other commercial variants could emphasize:

• No sucrose.
• No alcohol.
• No artificial color.
• Titanium dioxide-free formulation.
• Reduced allergen profile.
• Halal or kosher-compatible excipient sourcing.
• Fewer excipients.
• Pediatric-friendly flavor.

These claims must be supported by the actual formulation and regional labeling rules. They can differentiate a generic product without changing the active ingredient.

What stability requirements apply to oseltamivir oral suspension?

The product requires two stability profiles: unopened powder and reconstituted suspension.

Unopened powder

The dry product must maintain:

• Assay and impurity profile.
• Powder flow and fill-weight control.
• Reconstitution performance.
• Flavor integrity.
• Microbiological quality.
• Container-closure protection from moisture.

Moisture uptake can cause clumping, alter reconstitution time, reduce powder flow, and accelerate degradation. High-barrier bottles, induction seals, desiccants, and moisture-controlled manufacturing can reduce this risk.

Reconstituted product

The reconstituted suspension must maintain quality during the labeled storage period. The development package normally evaluates:

Test area	Commercial significance
Assay and degradation products	Confirms chemical stability
pH	Controls taste, preservative function, and degradation
Appearance	Detects color change, aggregation, and caking
Redispersibility	Supports dose uniformity
Particle-size distribution	Influences sedimentation and mouthfeel
Microbial limits	Confirms product safety during use
Preservative effectiveness	Supports multi-dose packaging
Delivered dose	Confirms oral syringe and bottle performance

Oseltamivir oral suspension is commonly labeled with a limited post-reconstitution storage period. The exact period and storage condition depend on the approved product and must be supported by the product-specific label. [1]

What patents protect oseltamivir phosphate oral suspension?

The core oseltamivir compound and the original Tamiflu exclusivity position are mature. The principal commercial barrier is no longer a broad active-ingredient patent monopoly.

Roche's original Tamiflu patent estate included compound, process, and pharmaceutical composition claims. The key U.S. patent protection for the original product expired years ago, and FDA-approved generic oseltamivir products entered the market through ANDA pathways. The product is therefore exposed to conventional generic competition rather than biosimilar competition.

Potentially relevant intellectual-property categories include:

IP category	Relevance to oral suspension
Active-ingredient patents	Generally expired or commercially exhausted in major markets
Salt and polymorph patents	May affect crystallization, stability, or manufacturing
Formulation patents	Could cover taste masking, suspension stability, or excipient combinations
Method-of-use patents	Could address dosing or influenza prophylaxis populations
Manufacturing patents	May cover purification, crystallization, or scale-up
Device claims	Could cover bottle adapters, oral syringes, or dose-delivery systems
Packaging claims	Could address moisture protection or unit-dose presentation

A company developing a new oseltamivir suspension should conduct a current jurisdiction-specific freedom-to-operate review. The commercially relevant question is whether a later patent claims the proposed excipient combination, manufacturing process, container-closure system, or dosing device. A formulation patent can create a narrower barrier even when the active ingredient is off patent.

What is the Orange Book status of oseltamivir oral suspension?

Oseltamivir phosphate oral suspension is a small-molecule product regulated through the FDA's generic-drug framework. The reference listed drug is Tamiflu for oral suspension. FDA's Orange Book identifies the reference product and approved therapeutically equivalent products where applicable. [2]

A generic applicant must address listed patents and exclusivities through the ANDA certification framework. For a mature oseltamivir product, the commercial focus is generally on:

• Paragraph III certifications for expired patents.
• Paragraph IV certifications against any unexpired listed patents.
• Paragraph I or II certifications where applicable.
• Suitability of the proposed formulation and strength.
• Therapeutic equivalence and labeling requirements.

A Paragraph IV filing can trigger patent litigation under 21 U.S.C. section 355(j), but a formulation-specific applicant must first determine whether the relevant claim is listed in the Orange Book or is instead a non-listed patent that creates a separate freedom-to-operate issue. [3]

When does oseltamivir lose exclusivity?

The broad market exclusivity for oseltamivir has already ended in the United States. Generic oseltamivir products have been approved, and the product is not protected by biologic exclusivity.

Exclusivity element	Current commercial assessment
Original compound exclusivity	Expired
Original U.S. patent position	Expired for the principal product claims
Generic entry	Established
Pediatric exclusivity	Historical exclusivity period, not a current barrier
Orphan exclusivity	Not the principal commercial framework
Biosimilar exclusivity	Not applicable
Potential later formulation patents	Must be reviewed claim by claim

The remaining barriers are operational and regulatory: stable supply of active pharmaceutical ingredient, seasonal manufacturing capacity, adequate pediatric labeling, taste acceptance, and reliable distribution during influenza surges.

What commercial opportunities exist for oseltamivir oral suspension?

Pediatric-focused generic

The largest formulation opportunity is a better pediatric product rather than a new indication. Differentiation can come from:

• Improved taste.
• Easier reconstitution.
• Lower viscosity.
• Better oral-syringe compatibility.
• Clearer dosing instructions.
• Smaller bottle or lower reconstitution volume.
• More robust in-use stability.
• Sugar-free positioning.

Pediatric demand is clinically important because capsule swallowing is difficult for many young patients. The product should support weight-based dosing with a graduated oral syringe and minimize conversion errors between milligrams and milliliters.

Institutional and government procurement

Influenza preparedness programs value shelf life, rapid deployment, domestic or diversified sourcing, and packaging that can be distributed efficiently. A powder-for-suspension product has advantages over a ready-to-use liquid because it is lighter and generally more stable before reconstitution.

Commercial opportunities include:

• Government stockpiles.
• Hospital systems.
• Long-term-care facilities.
• Pediatric clinics.
• Public-health emergency contracts.
• Seasonal pharmacy distribution.

Procurement buyers may prioritize supply assurance over marginal price differences during influenza outbreaks.

Ready-to-use liquid formulation

A ready-to-use suspension could reduce preparation errors and improve convenience. It would also create technical and commercial burdens:

• Lower stability than a dry powder.
• Greater shipping weight.
• Higher preservative exposure.
• More demanding container-closure requirements.
• Greater microbial-control risk.
• Higher logistics cost.

A ready-to-use version could be attractive for hospitals, emergency departments, and caregivers who need immediate dosing. The product would require a clear value proposition because the existing powder format is established.

Unit-dose and sachet formats

Unit-dose packaging could reduce cross-contamination and improve institutional workflow. Sachets or small-volume bottles may support:

• Emergency dispensing.
• Pediatric clinic use.
• Government distribution.
• Reduced medication waste.
• Simplified reconstitution.

The main limitations are filling accuracy, moisture protection, water addition at the point of use, and the need for an appropriate dosing device.

Combination and co-packaging opportunities

A co-pack with an oral syringe, bottle adapter, and standardized dosing chart can reduce medication errors. A co-pack with antipyretic products would require careful regulatory and commercial analysis and could create pediatric safety concerns. The stronger near-term opportunity is a dosing system rather than a pharmacologic combination.

Which companies are challenging the oseltamivir market?

The market includes Roche as the originator and multiple generic manufacturers that have obtained or pursued FDA approvals. Competition is based on API access, manufacturing cost, quality systems, distribution, and seasonal inventory planning.

Generic manufacturers with established oral-liquid capabilities have an advantage because oseltamivir suspension requires more than simple capsule production. The formulation must meet reconstitution, taste, preservative, and in-use stability requirements. Companies with government-contracting capacity can also compete for stockpiling and outbreak-response business.

The most defensible commercial position is likely to come from a combination of:

• Reliable API sourcing.
• A differentiated pediatric excipient system.
• Strong seasonal forecasting.
• High-barrier packaging.
• Competitive reimbursement and wholesale pricing.
• Government and institutional contracting.

How strong is the patent estate for oseltamivir oral suspension?

The broad patent estate is weak as a current barrier because the original active-ingredient and product exclusivity periods have ended. A narrowly drafted later formulation or device patent could have value if it covers a clinically meaningful improvement and survives validity and infringement challenges.

Factor	Assessment
Core molecule protection	Low current barrier
Generic entry risk	High
Formulation patent risk	Product-specific and potentially material
Manufacturing patent risk	Relevant if a protected process is required
Regulatory exclusivity	Limited current barrier
Biosimilar risk	None
Supply-chain barrier	Moderate
Taste and pediatric usability barrier	Moderate
Government procurement opportunity	Moderate to high during outbreaks

Patent strength should be assessed claim by claim. A broad claim to oseltamivir suspension is likely to face substantial validity and obviousness pressure in a mature generic market. A narrower claim tied to a defined excipient ratio, stability result, taste score, particle-size distribution, or delivery system may have stronger commercial relevance but a narrower blocking scope.

What generic launch scenarios exist?

Low-cost conventional generic

The manufacturer uses a conventional powder-for-suspension formulation with standard flavoring and packaging. This strategy offers the fastest route to price competition but limited differentiation.

Premium pediatric generic

The manufacturer invests in sensory testing, a proprietary flavor system, improved redispersibility, and a high-quality dosing device. The product can target caregivers, pediatric practices, and hospital formularies.

Institutional stockpile product

The product emphasizes long shelf life, moisture protection, scalable production, and government procurement requirements. Packaging may prioritize inventory control over consumer convenience.

Ready-to-use suspension

The manufacturer targets hospitals and urgent-care settings with a liquid product that eliminates reconstitution. The main risks are stability, microbial control, shipping cost, and manufacturing complexity.

How does oseltamivir suspension compare with oseltamivir capsules?

Attribute	Oral suspension	Capsules
Pediatric usability	Stronger for young children	Limited where swallowing is difficult
Manufacturing complexity	Higher	Lower
Taste risk	High	Low because drug is enclosed
Packaging burden	Bottle, closure, syringe	Blister or bottle
Dose flexibility	Strong, weight-based dosing	Limited by capsule strengths
In-use stability	Must be demonstrated after reconstitution	Generally simpler
Shipping efficiency	Good before reconstitution	Good
Medication-error risk	Higher if dose conversion is unclear	Lower for fixed strengths
Commercial differentiation	Higher	Lower in a mature generic market

Key Takeaways

• Oseltamivir phosphate oral suspension is a mature small-molecule generic opportunity, not a biosimilar opportunity.
• The main formulation challenge is bitterness, followed by suspension uniformity, preservation, and dose accuracy.
• The reference formulation uses sorbitol, saccharin sodium, tutti-frutti flavor, sodium benzoate, monosodium citrate, and titanium dioxide, according to FDA labeling.
• Core oseltamivir patent protection has expired in the United States, while later formulation, process, packaging, or device patents require product-specific review.
• The strongest commercial opportunities are pediatric taste masking, easier reconstitution, improved dosing systems, sugar-free or titanium dioxide-free positioning, institutional supply, and government stockpiling.
• A premium pediatric generic can create more value than an undifferentiated low-cost product, but it requires sensory, stability, and human-factors development.
• Ready-to-use liquid formulations offer convenience but carry higher stability, microbiological, packaging, and logistics costs.
• Generic launch success will depend more on API security, manufacturing reliability, seasonal forecasting, and regulatory execution than on broad molecule patents.

FAQs

Is oseltamivir phosphate oral suspension a biologic?

No. Oseltamivir phosphate is a chemically synthesized small molecule. Follow-on products are reviewed through the ANDA pathway, not the biosimilar pathway.

Can oseltamivir suspension be formulated without titanium dioxide?

Yes, a follow-on product can use a different opacifier or omit titanium dioxide if the resulting formulation meets quality, stability, appearance, and labeling requirements. The alternative must be justified in the ANDA.

What is the main reason to develop a new oseltamivir suspension?

The strongest reason is improved pediatric usability through better taste, easier reconstitution, more reliable dose delivery, or longer in-use stability. A new product is unlikely to obtain meaningful value from active-ingredient exclusivity.

Is a ready-to-use oseltamivir liquid commercially superior to powder?

Not automatically. A ready-to-use liquid is more convenient but has greater shipping weight, microbial-control requirements, and stability risk. Its value is strongest in institutional settings where immediate administration offsets those costs.

Can excipients create patent protection for oseltamivir suspension?

Yes. A patent may claim a defined excipient system, ratio, particle-size profile, stability result, taste-masking mechanism, packaging configuration, or delivery device. The commercial strength depends on claim scope, validity, infringement evidence, and whether the patent is listed or unlisted.

References

1. U.S. Food and Drug Administration. (2021). Tamiflu (oseltamivir phosphate) prescribing information. Genentech USA, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2022). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

5. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. https://www.fda.gov/